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Background: Accumulated evidence has indicated a correlation between S100A4 expression and colorectal cancer
(CRC) progression. However, its prognostic significance for patients with CRC remains inconclusive. To clarify their
relationship, a meta-analysis of the relevant published studies was performed.
Method: PubMed, Cochrane Library, and Web of Science databases were electronically searched. All studies
evaluating the prognostic value of S100A4 expression in CRC patients regarding survival and a series of
clinicopathological parameters were included. The effect of S100A4 expression on the overall survival (OS) and
disease-free survival (DFS) were measured by pooled hazard ratios (HRs) and 95% confidence intervals (CIs), while
the effect of S100A4 expression on the clinicopathological parameters were measured by the pooled odds ratios
(ORs) and their 95% CIs.
Results: Eleven studies (2,824 patients in total) were included in the meta-analysis. Overall, S100A4 overexpression was
significantly associated with worse OS (HR = 1.90, 95% CI: 1.58–2.29, P <0.001), and worse DFS (HR = 2.16, 95% CI: 1.53–3.05,
P <0.001) in patients with CRC. Subgroup analyses showed that S100A4 overexpression was significantly correlated
with poor OS in Asian, European, and Australian patients and patients treated with surgery or chemotherapy.
Additionally, there were significant associations between S100A4 expression and several clinicopathological parameters
(tumour location, lymph node metastasis, nodal status, TNM stage, and tumour depth).
Conclusions: This meta-analysis indicates that S100A4 overexpression seems to correlate with tumour progression and
poor prognosis of CRC patients. It may be a useful marker to predict progression and prognosis of CRC.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
8643820431072915
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Colorectal cancer (CRC) is one of the most frequently
occurring cancers worldwide; cancer-related deaths have
thus become a major public health challenge [1], being
the second and third most common causes of cancer
deaths in the USA and Europe, respectively [2,3]. In
Asia, CRC is the fourth leading cause of mortality by
cancer, and its incidence is increasing [4]. Therefore, it is* Correspondence: qinxue919@126.com; lis8858@126.com
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stated.clear that, despite decades of advances in its prevention
and treatment, CRC remains a substantial cause of death
[5]. The 5-year survival rate is approximately 85% after
surgical resection performed in the early stages of CRC;
however, the rate is significantly decreased (<50%) in
stage III CRC with lymph node metastasis [6]. Distant
metastasis (stage IV) is the most frequent cause of treat-
ment failure and forms the highest mortality of CRC,
with a 5-year survival rate of <5% [7,8]. Therefore, early
detection of tumorigenesis and metastases is critical to
improving treatment strategies and patient outcomes.
Nevertheless, suitable predictors that can be widely used
in clinical settings are not currently available andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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patients remain important obstacles for successful can-
cer treatment. The development of reliable biomarkers
and simple tests that are routinely applicable for early
detection, progression, prognosis, and therapy moni-
toring is strongly needed.
S100A4, also known as metastatin (Mts1) or p9Ka [9],
belongs to the S100 family that contains two calcium
binding sites, including a canonical EF-hand structural
motif, and is classified as a metastasis-related gene [10].
S100A4 possesses a wide range of biological functions
such as regulation of angiogenesis, motility, invasion,
and cell survival [10]. A large number of experimental
studies have linked the S100A4 gene product to the meta-
static phenotype of cancer cells [10]. Clinical evidence has
also indicated a correlation between S100A4 overexpres-
sion and prognosis in several cancer types, such as bladder
cancer [11], breast cancer [12], esophageal-squamous can-
cer [13], gastric cancer [14], lung cancer [15], and pan-
creatic cancer [16]. In particular, growing evidence has
suggested an association between S100A4 overexpres-
sion and the clinicopathological outcomes and prognosis
in CRC [17-32]. Nevertheless, inconsistent data have
emerged regarding the ability of S100A4 to predict disease
progression and survival in CRC. Multiple studies have
shown that CRC patients with S100A4 overexpression
have worse overall survival (OS) and disease-free survival
(DFS) [17,21,23,24,26,27,29,32]; however, one study failed
to achieve statistical significance on this association in a
multivariate analysis [22].
To clarify the relationship between S100A4 expression
level and its prognosis value for patients with CRC, a de-
tailed meta-analysis of the relevant published studies
was performed. To the best of our knowledge, this is the
first meta-analysis showing the prognostic significance
of S100A4 expression in CRC.
Methods
This systematic review and meta-analysis was carried
out in accordance with the Preferred Reporting Items
for Systematic reviews and Meta-Analyses (PRISMA)
statement [33].
Search strategy and selection criteria
Studies were identified by searching PubMed, Cochrane
Library, and Web of Science databases (last search up-
dated to July 7, 2013). The following search strategy was
used: “colon cancer OR colon carcinoma OR rectum can-
cer OR rectum carcinoma OR colorectal cancer OR colo-
rectal carcinoma” AND “S100* OR S100A4”. No language
restrictions were applied. To ensure that no studies were
overlooked, the reference lists of relevant articles and re-
view articles were manually searched to identify additional
studies.Studies were included if they fulfilled the following cri-
teria: i) reporting explicit methods for the detection of
S100A4 expression in CRC; ii) their endpoints were to
evaluate the prognostic value of S100A4 expression in
CRC patients regarding OS, DFS, and a series of clinico-
pathological parameters; and iii) provided a relative risk
(RR) estimate (risk ratio, rate ratio) or odds ratio (OR)
with the corresponding confidence interval (CI) or suffi-
cient data to calculate them. When multiple publications
on the same study population were identified or when
study populations overlapped, only the most recent or
complete article was included in the analysis. The com-
prehensive database search and study selection were
carried out independently by Y. Liu and S. Li. Differ-
ences were settled by consensus involving the third au-
thor (W. Tang).
Data extraction
Two authors (X. Qin and Y. Liu) independently extracted
information using predefined data abstraction forms. Dis-
crepancies were resolved by the third author (Y. Liu) inde-
pendently extracting disputed data and consensus was
reached by discussion. The following information was ex-
tracted from each included trial: i) study information (in-
cluding first author’s name, year of publication, country,
and sample size); ii) patient information (including age,
sex, type of treatment, tumour characteristics); iii) follow-
up time; iv) outcome measures: data allowing us to esti-
mate the impact of S100A4 expression on DFS, OS, and
clinicopathological parameters.
Statistical methods
Included studies were divided into three groups for ana-
lysis: OS, DFS, and clinicopathological parameters. S100A4
was considered as having a ‘high’ or ‘low’ expression ac-
cording to the cut-off values provided by the authors in
each publication, because of variation on the definition for
the ‘high’ or ‘low’ expression of S100A4 between studies.
Hazard ratios (HRs) and their 95% CIs were combined to
measure the effective value. If HRs and corresponding 95%
CIs were not available, they were calculated from available
numerical data using methods reported by Parmar et al.
[34]. Data from the Kaplan-Meier survival curves were
read using Engauge Digitizer version 4.1. Three independ-
ent persons read the curves to reduce reading variability.
For the pooled analysis of the relation between S100A4
overexpression and clinicopathological parameters, ORs
and their 95% CIs were combined to give the effective
value. The impact of S100A4 on prognosis was considered
statistically significant if the 95% CI for the overall HR did
not overlap 1.
Statistical heterogeneity was assessed by visual inspec-
tion of forest plots, by performing the χ2 test (assessing
the P value), and by calculating the I2 statistic [35,36]. If
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cating the presence of heterogeneity, a random-effects
model (the DerSimonian and Laird method) was used
[37]; otherwise, the fixed-effects model (the Mantel-
Haenszel method) was used [38]. To investigate the possible
sources of the heterogeneity, we conducted subgroup ana-
lyses based on the following three aspects: first line treat-
ment, type of method used to obtain the HR, and study
regions. A sensitivity analysis was conducted to evaluate
sources of heterogeneity both in the overall pooled estimate
as well as within the subgroups. In addition, potential
sources of heterogeneity were investigated through graphical
methods such as the Galbraith plot [39]. We assessed
publication bias graphically using a funnel plot and
quantitatively using the Begg rank correlation test and
the Egger regression asymmetry test [40,41]. If publica-
tion bias was observed, we adjusted for the effect by
the use of the Duval and Tweedie trim-and-fill method
[42]. All P <0.05 (two-sided) were considered as sig-
nificant unless otherwise specified. All analyses were
performed using STATA, version 12.0 (StataCorp, College
Station, TX, USA).
Results
Study selection and characteristics
The initial search yielded 424 records. After exclusion of
duplicate and irrelevant studies, 13 eligible published
studies were finally retrieved for the meta-analysis [17-29].
Three studies were excluded due to insufficient data to
allow for estimation of the HR and OR [30-32], and two
studies were excluded since they only evaluated the correl-
ation between S100A4 with Dukes stage [43,44]. The
process of article identification, inclusion, and exclu-
sion is summarized in Figure 1 and the main charac-
teristics are listed in Table 1.Records identified and screened after duplicates rem
389 articles excluded accor
Revealed no relation, 
abstract
Full-text articles reviewed for more detailed evalua
Articles accepted for analysis (n = 13)
22 articles excluded:
1. Evaluating other S100 prote
2. Insufficient data to allow fo
3. Only evaluating the correlat
Figure 1 Flow chart depicting the selection of eligible studies.S100A4 expression and OS in colorectal cancer
Overall, eight studies including 2,615 patients reported data
on S100A4 expression and OS in CRC [17,21-24,26,27,29].
Meta-analysis of the eight studies regarding the prognostic
value of S100A4 expression showed that high S100A4
levels were significantly associated with poor OS (HR =
1.90, 95% CI: 1.58–2.29, P <0.001; Figure 2), with no het-
erogeneity between studies (P = 0.48, I2 = 0.0%; Table 2).
Further subgroup analysis based on CRC patients’ treat-
ment showed that elevated S100A4 levels were markedly
related with worse OS in CRC patients treated by surgery
(pooled HR = 2.27, 95% CI: 1.74–2.96, P <0.001), without
any evidence of heterogeneity (P = 0.68, I2 = 0.0%).
Moreover, high S100A4 levels were also significantly
associated with lower OS in CRC patients treated by
surgery plus chemotherapy (pooled HR = 1.60, 95% CI:
1.24–2.07, P = 0.0004; for heterogeneity: P = 1.00, I2 = 0.0%).
In subgroup analysis based on type of method used to obtain
the HR, the result of significance and heterogeneity
remained practically unchanged. A statistically signifi-
cant association was observed between S100A4 expres-
sion and the prognosis for patients with CRC among
different study regions. The pooled HR was 2.08 (95%
CI: 1.55–2.80, P <0.001) among studies from Asia, 2.18
(95% CI: 1.11–4.28, P = 0.02) among studies from Europe,
and 1.6 (95% CI: 1.10–2.20, P = 0.008) among studies
from Australia. Table 2 shows the main meta-analysis
results.
S100A4 expression and DFS in colorectal cancer
Only three studies reported data on S100A4 expression
and DFS in CRC [21,25,29]. Combined data from the
three studies suggested that increased S100A4 levels were
significantly correlated with DFS in CRC patients, yielding
a combined HR of 2.16 (95% CI: 1.53–3.05, P <0.001),oved (n = 424)
ding to titles and abstracts:
review, letter, comment, case report, only 
tion (n=35)
in rather than S100A4 (n = 17)
r estimation of the HR (n = 3)
ion between S100A4 with Dukes stage (n = 2)






















Gongoll, 2002 [17] Germany 709/296 Surgery 318/391 606/103 <2: 42 2–5:
440 >5: 227
I/II: 218 NR IHC > 50% cancer
cells stained
114 (16.1) OS, Clinicopathological
parameters
III/IV: 491





73 (30.2) OS, DFS
III: 77
Kwak, 2010 [22] South Korea 127/51 Surgery 55/72 73/54 NR I/II: 73 Median 58.7,
range 1.1-101.8
IHC 20% of tumor
cells stained
45 (35.4) OS, Clinicopathological
parameters
III/IV: 54
Wang, 2010 [23] China 115/52 Surgery 77/38 97/18 NR NR Median 62,
range 4-76
IHC ≥ 20% tumor
cells stained
66 (57.4) OS, Clinicopathological
parameters
Huang, 2011 [24] China 112/53 Surgery 47/65 59/53 ≤5: 74; >5: 38 I/II: 57 NR IHC > 35% cancer
cells stained
57 (50.9) OS, Clinicopathological
parameters
III/IV: 55
Kang, 2012 [26] Korea 526/204 Surgery 321/205 255/271 NR NR Median 40.1,
range 2–69
IHC 30% of tumor
cells stained,
136 (25.9) OS, Clinicopathological
parameters
Kho, 2012 [27] Australia 409/159 Mixed 451/0 NR < 5: 205
≥ 5: 204
I/II: 256 Median 34.6,
range 0.4-351
IHC ≥ 50% cancer
cells stained
45 (11.0) OS, Clinicopathological
parameters
III/IV: 133
Lee, 2013 [29] Korea 333/144 Surgery NR 240/93 NR I/II: 187 At least 5 years IHC Stained cells
were grade one
267 (50.0) OS, DFS, Clinicopathological
parameters
III/IV:146
Stein, 2011 [25] Germany 375/205 Mixed 185/190 341/34 NR I/II: 139 Median 24.3 RT-PCR 0.387 S100A4 143 (49.7) DFS
III/IV: 61 mRNA expression,
% calibrator





Hemandas, 2006 [19] Singapore 54/23 Mixed 34/20 46/8 <2: 5 NR Median 65,
rang 3– 104












Giraldez, 2013 [28] Spain 228/95 CHT 228/0 NR NR II: 78 Median 42, RT-PCR Risk score: 4.076 NR Clinicopathological
parameters
III: 150 Range 6–152















Figure 2 Forest plot of the association between high S100A4 expression and overall survival (OS) stratify by treatment.
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I2 = 0.0%) (Figure 3, Table 2). The number of studies was
too small to perform a further subgroup analysis.S100A4 expression and clinicopathological parameters
The studies reporting data on the individual clinicopath-
ological parameter are shown in Table 2. When the data
was pooled, there were significant associations between
high S100A4 expression and tumour location, lymph
node metastasis, nodal status, TNM stage, and tumour
depth. Specifically, the pooled ORs (95% CIs) were as
follows: 1.34 (1.06–1.69) for tumour location (rectum vs.
colon), 2.62 (1.40–4.90) for lymph node metastasis (yes
vs. no), 2.68 (1.57–4.55) for nodal status (N1–2 vs. N0),
3.03 (1.48–6.20) for TNM stage (III/IV vs. I/II), and 1.82
(1.35–2.46) for tumour depth (T 3/4 vs. T 1/2). How-
ever, the data only suggested an evident trend towards a
worse prognosis but no significant association between
high S100A4 expression and CRC patients’ age (old vs.
young), gender (female vs. man), differentiation (poorly
vs. well and moderately), distant metastasis (M1 vs. M0),
tumour size (size ≥5 cm vs. <5 cm), vascular invasion
(yes vs. no), and recurrence (yes vs. no) (Table 2, Additional
file 1: Figure S1).Sensitivity analyses
Sensitivity analyses were performed to examine whether
the effect estimate was robust by sequential omission of
individual studies. When a single study at a time was de-
leted from the above analyses, the corresponding pooled
HR and OR were not significantly altered (data notshown), suggesting the robustness of the presented
results.
Publication bias
Begg’s funnel plot and Egger’s test were performed to as-
sess the publication bias of studies in all situations
(Table 2). Publication bias was only observed in the as-
sociations between S100A4 expression and OS in pa-
tients with CRC (P = 0.06 for Begg’s test; P = 0.03 for
Egger’s test) (Figure 4A). After adjustment with the
trim-and-fill method (Figure 4B), the pooled association
between S100A4 expression and OS in patients with
CRC was also significant (fixed model: HR = 1.72, 95%
CI: 1.45–2.05, P <0.00001; random model: HR = 1.74,
95% CI: 1.39–2.17, P <0.0001), and with no significant
heterogeneity (P = 0.155), all of which indicate that the
results of these meta-analyses were relatively stable and
that it is unlikely that publication bias may have affected
the results.
Discussion
To date, surgical resection remains the preferred treat-
ment strategy for CRC patients; however, not all CRC
patients derive clinical benefit from such a treatment [6].
There has been special interest in identifying a novel
predictive and prognostic marker to help guide clinical
therapy for patients with CRC. During the past few
years, many molecular markers, such as TP53 [45],
KRAS, and BRAF [46], have been investigated. However,
because of their limited accuracy or the lack of an ad-
equate validation, they have not become routinely used
in clinical practice. In recent years, a number of studies
Table 2 Main meta-analysis results
Analysis No. ofstudies
No. of




I2 (%) p Begg’s p Egger’s p
Overall survival (OS) 8 2615 1.90 (1.58–2.29) < 0.001 F 0.0 0.48 0.06 0.03
Subgroup 1: treatment
Surgery 6 1922 2.27 (1.74–2.96) < 0.001 F 0.0 0.68 0.26 0.27
surgery + chemotherapy 2 693 1.60 (1.24–2.07) < 0.001 F 0.0 1.00 - -
Subgroup 2: type of method
used to obtain the HR
Reported HR 6 2167 1.89 (1.53–2.35) < 0.001 F 23.3 0.26 0.13 0.06
Calculated HR 2 448 1.92 (1.34–2.74) < 0.001 F 0.0 0.89 - -
Subgroup 3: study regions
Asia 5 1213 2.08 (1.55–2.80) < 0.001 F 0.0 0.83 0.09 0.07
Europe 2 951 2.18 (1.11–4.28) 0.02 R 72.8 0.06 - -
Australia 1 451 1.6 (1.10–2.20) 0.008 - - - - -
Disease-free survival (DFS) 3 950 2.16 (1.53–3.05) < 0.001 F 0.0 0.667 1.000 0.825
Clinicopathological parameters OR (95% CI)
Age (old vs. young) 7 2040 1.24 (0.99–1.56) 0.06 F 0.0 0.91 1.00 0.87
Gender (female vs. man) 7 2113 1.15 (0.93–1.43) 0.21 F 23.2 0.25 1.00 0.81
Tumor location (rectum vs. colon) 6 1662 1.34 (1.06–1.69) 0.01 F 0.0 0.97 0.71 0.57
Differentiation (poorly vs. well
and moderately)
7 1340 1.04 (0.75–1.44) 0.80 F 0.0 0.61 0.55 0.22
Lymph node metastasis (yes vs. no) 6 1671 2.62 (1.40–4.90) 0.003 R 83.7 0.00 0.26 0.07
Nodal status (N1 ~ 2 vs. N0) 4 1230 2.68 (1.57–4.55) < 0.001 R 59.9 0.06 0.09 0.02
Distant metastasis (M1 vs. M0) 3 768 3.22 (0.65–15.84) 0.15 R 75.6 0.02 1.00 0.17
TNM stage (III/IV vs. I/II) 5 1732 3.03 (1.48–6.20) 0.002 R 82.4 0.00 0.81 0.20
Tumor depth (T 3/4 vs. T 1/2) 6 1922 1.82 (1.35–2.46) < 0.001 F 0.0 0.49 0.71 0.99
Tumor size (size≥ 5 cm vs. < 5 cm) 6 1523 0.88 (0.67–1.16) 0.37 F 0.0 0.48 1.00 0.99
Vascular invasion (yes vs. no) 2 977 1.29 (0.83–2.03) 0.26 F 0.0 0.48 - -
Recurrence (yes vs. no) 2 335 2.03 (0.87–4.73) 0.100 R 68.2 0.076 - -
HR = hazard ratio Model; OR = Odds ratio; CI = confidence interval; F = fixed-effects model; R = random-effects model.
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S100A4 expression and the survival and prognosis of
CRC patients, although consistent results have not been
reported. Therefore, we conducted a meta-analysis of
the evidence obtained from all published studies in order
to provide a quantitative reassessment of the association.
To our knowledge, this is the first and the most compre-
hensive meta-analysis, to date, evaluating the association
between S100A4 expression and CRC risk.
This study involves the meta-analysis of published data
regarding S100A4 expression and its association with
progression and prognosis in CRC. We observed a posi-
tive relationship between S100A4 overexpression and
worse survival overall and among subgroups defined by
treatment, type of method used to obtain the HR, and
study regions. Furthermore, we also observed a signifi-
cant association between high S100A4 expression andseveral clinicopathological parameters (lymph node me-
tastasis, nodal status, TNM stage, and tumour depth).
Eight studies were included in the OS analysis. A
European study evaluating the association S100A4 over-
expression and OS was excluded because of insufficient
data to estimate HR [32]. This study investigated 33
colon cancer patients who underwent colonic surgery
and evaluated S100A4 expression by RT-PCR, demon-
strating that colon patients with high S100A4 expression
had a significantly worse OS [32]. This result was con-
sistent with our overall analysis; it suggests that our ana-
lyses were credible enough.
S100A4 was first described in 1984 as an upregulated
mRNA in a rodent model of mammary metastasis [47].
Since then, it has been reported to be involved in the
pathogenicity of several diseases [48,49], and has been as-
sociated with patients’ outcome in a number of tumour
Figure 3 Forest plot of the association between high S100A4 expression and disease free survival (DFS).
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experimental studies examining the prognostic value of
S100A4 expression published thus far, have been retro-
spective studies. On the other hand, most S100A4 expres-
sion studies have focused on tumours at multiple stages;
there have also been several previously published reviews
on this topic [10,52-54]. These reviews have shown a
qualitative description about the multiple roles of S100A4
protein in tumorigenesis and metastasis and the inverted
association of tumour patients’ prognosis. However, these
reviews could not give a precise estimation of survival cor-
relation. The landmark study by Gongoll et al. [17],
showed that high S100A4 expression was correlated withFigure 4 Funnel plots of publication bias for overall survival (OS) ana
method adjustment).worse prognosis in patients that received surgery. Con-
versely, it was concluded that S100A4 seemed to be a
more valuable prognostic factor than the nodal lymph
node status (pN), which lost its prognostic value in the
multivariate Cox model if S100A4 was added. Subse-
quently, more than twelve studies investigated this topic
and practically demonstrated a significant association be-
tween S100A4 overexpression and worse prognosis in
CRC patients [17-29]. Our results were consistent with the
previous experimental studies, and we obtained a more re-
fined evaluation after pooling of the available evidence.
Metastasis is the main cause of death in patients with
CRC. Clinicopathological parameters, such as poorlylysis. (A the original funnel plots; B funnel plots after trim-and-fill
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TNM stage, are considered the pathological risk factors
for lymph node metastasis [55]. Nevertheless, these fea-
tures are still insufficient to predict the existence of me-
tastasis and are currently critically discussed, pointing to
the need for new factors, either morphological or mo-
lecular, that could more precisely stratify patients into
different risk categories. One candidate biomarker for
the progression and prognosis of multiple malignant tu-
mours is S100A4. Although the association of S100A4
with tumour progression has been explored in recent
years, the available data have not been analysed compre-
hensively until now. As expected, in the present meta-
analysis, the results suggested a significant association
between high S100A4 expression and advanced TNM
stage, nodal status, and tumour depth, as well as the
presence of lymph node metastasis. Pooled data also
suggested an evident trend towards higher S100A4 ex-
pression with poor differentiation, the presence of vascu-
lar invasion and distant metastases, although the
statistical significance did not reach the significant level.
Taken together, the pooled results in our meta-analysis
support the hypothesis that S100A4 overexpression
might promote CRC invasion and metastasis, and thus
lead to a poor prognosis of CRC.
Obviously, the molecular mechanisms of S100A4 pro-
motion of tumour progression need a more comprehen-
sive understanding. Moreover, the association between
S100A4 expression and worse survival should be ana-
lysed through larger multicentre prospective studies
using standardized unbiased laboratory methods and
well matched patients and controls. Another promising
area should be the discovery of novel therapeutic strat-
egies targeting S100A4 and suggested inhibitors, which
may serve in the development of treatments for CRC
metastasis.
The strengths of the present study were the rigorous
search strategy, the avoidance of a language limitation, and
the stringent inclusion criteria. Moreover, studies evaluat-
ing S100A4 expression through all available methods were
included, which avoided the limitation of data and non-
credible results. In addition, no significant heterogeneity
was observed on the pooled survival analyses, which indi-
cated that the statistical results were robust. Furthermore,
the results of sensitivity analysis, subgroup analysis, and
adjusting for the effect of publication bias by the trim-
and-fill method did not alter and did not draw differ-
ent conclusions, indicating that our results were strong.
To our knowledge, this is the first meta-analysis on the as-
sociation between S100A4 expression and OS, DFS and
clinicopathological parameters in CRC.
The data currently available on S100A4 expression
and CRC are somewhat promising, but these findings
must be further confirmed by large prospective studiesfor the following reasons. First, studies included in the
meta-analysis were mainly retrospective analyses; it is
possible that other unknown confounders will bias the
data. Second, the number of studies classified into
pooled DFS group analysis was limited, preventing firm
conclusions. Third, some publication bias was observed
although significance did not alter after adjusting by the
trim-and-fill method. Fourth, cut-off values of S100A4
high or low expression were different in the studies. The
different cut-off value between studies may affect the re-
sults and account for the inconsistencies. However, it
was difficult to provide an exact definition for ‘high’ or
‘low’ expression in view of the different S100A4 detec-
tion methods used. Therefore, future studies on this
topic should use a consistent definition for ‘high’ or ‘low’
expression and use the same S100A4 detection method.
Finally, subgroup analyses cannot be performed by
Dukes stages due to the heterogeneity of tumour stages
involved in individual studies. Given the limitations
listed above, our results should be interpreted with
caution.Conclusions
This systematic review and meta-analysis demonstrates
that high S100A4 expression seemed to correlate with
tumour progression and prognosis of CRC patients
treated by surgery or chemotherapy in different study re-
gions. S100A4 may be a useful marker to predict devel-
opment, progression, and prognosis of colorectal cancer.Additional file
Additional file 1: Figure S1. Forest plot showing results of studies on
the associations between S100A4 expression and clinicopathological
parameters (age, gender, lymph node metastasis, tumor-node-metastasis
(TNM) stage, differentiation, tumor depth, tumor size, tumor location,
vascular invasion and recurrence).
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